Table 1 Demographic and clinical characteristics of patients with UC
axSpA group (n1 = 14) | non-axSpA group (n2 = 59) | t/χ2/Z | P value | |
|---|---|---|---|---|
Male (%) | 9 (64.3) | 39 (66.1) | 0.000 | 1.000 |
BMI, kg/m2 | 21.06 ± 2.60 | 21.53 ± 2.93 | 0.549 | 0.585 |
Smoking history, y | 4 (28.6) | 12 (20.3) | 0.096 | 0.756 |
UC onset time, y | 37.71 ± 9.20 | 42.39 ± 14.57 | 1.506 | 0.142 |
HLA-B27 + | 6 (42.9%) | Not measured | ||
Disease staging | - | 1.000 | ||
Active phase | 13 (92.9) | 55 (93.2) | ||
Remission | 1 (7.1) | 4 (6.8) | ||
Clinical typing | ||||
Initial | 2 (14.3) | 7 (11.9) | 0.000 | 1.000 |
Chronic recurrent | 12 (85.7) | 52 (88.1) | ||
Montreal classification of extent | 2.638 | 0.267 | ||
E1 (proctitis) | 1 (7.1) | 13 (22.0) | ||
E2 (left-sided; distal) | 4 (28.6) | 21 (35.6) | ||
E3 (pancolitis) | 9 (64.3) | 25 (42.4) | ||
Modified Truelove Witts classification | 4.369 | 0.113 | ||
Mild | 4 (28.6) | 16 (18.6) | ||
Moderate | 4 (28.6) | 32 (54.2) | ||
Severe | 6 (42.9) | 11 (27.1) | ||
Modified Mayo score | 8.43 ± 1.87 | 7.15 ± 2.27 | -1.947 | 0.055 |
ESR > 20 mm/h | 7 (50.0) | 19 (32.2) | 0.883 | 0.347 |
CRP > 10 mg/L | 8 (57.1) | 10 (16.9) | 7.795 | 0.005 |
Medication History | ||||
5-Amino salicylic acids | 9 (64.3) | 44 (74.6) | 0.196 | 0.658 |
Infliximab | 2 (14.3) | 6 (10.2) | 0.000 | 1.000 |
Vedolizumab | 0 (0.0) | 5 (8.5) | - | 0.576 |